SECONDARY ACUTE MYELOID LEUKEMIA

This study looks at a modified approach to prevent and treat cytomegalovirus (CMV) infection in people who have had a donor stem cell transplant for blood cancers or related disorders. About 153 participants will be monitored to see if delaying or adjusting anti-CMV therapy can s…

This early-phase study tests a combination of three drugs—bortezomib, sorafenib, and decitabine—in patients with acute myeloid leukemia (AML), especially those who are older or whose cancer has returned. The main goal is to find the safest dose and understand side effects. The st…

This study tests whether adding an immunotherapy drug (pembrolizumab) to standard treatment (azacitidine and venetoclax) can help older adults with acute myeloid leukemia (AML) achieve deeper remission and lower the chance of the cancer coming back. About 60 participants who are …

This study tested a combination of two drugs—azacitidine and gemtuzumab ozogamicin—in 133 adults aged 60 and older with untreated acute myeloid leukemia (AML). The goal was to see how well the treatment worked at putting the cancer into remission and how safe it was. Participants…

This study is for people with high-risk acute leukemia or myelodysplastic syndrome (MDS). It tests a new, stronger conditioning regimen—combining targeted radiation (TMLI) with two chemotherapy drugs—given before a donor stem cell transplant. The goal is to find the safest dose t…

This study tests whether adding a drug called decitabine before standard chemotherapy can help more people with acute myeloid leukemia (AML) achieve remission. About 178 adults with AML that is not the most treatable type will receive either a low or high dose of decitabine follo…

This study looks at whether cognitive behavioral therapy (CBT) can help people with acute myeloid leukemia or lymphoma who feel very tired from their cancer or treatment. About 48 patients will learn new ways to think and act to better cope with fatigue, anxiety, and depression. …